Therapeutic Response

MET Exon 14 (Splice Site) status confers therapeutic sensitivity to Tepotinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Tepmetko (tepotinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
Tepmetko (tepotinib) [product monograph]. HC. Health Canada approved tepotinib for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymalepithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations.